Analysis for CI
- 📈 Growth — 28/30
- 💰 Profitability — 16/20
- 🏦 Financial Health — 15/20
- 💵 Valuation — 12/20
- ⚠️ Risk — 6/10
Summary:
📈 Growth & Financial Trajectory
From the eight-quarter span, revenues rose from about $57.3B in 2024-Q1 to about $72.5B in 2025-Q4, a roughly 26-27% uplift. Net income fluctuated but remained positive across the period, peaking around $1.97B in 2025-Q3 and ending near $1.27B in 2025-Q4, indicating improving earnings power despite quarterly variability.
💰 Margins & Cash Flow
Gross margins hovered near 20%, with operating income turning positive in most quarters. Cash generation was solid, highlighted by Net Cash Flow From Operating Activities around $6.15B in 2025-Q4, and generally positive across recent quarters. Investing cash flow was negative, reflecting ongoing capital use, while financing activity varied by period.
🛡️ Balance Sheet & Liquidity
Balance sheet strength is evident: assets around $150B+, liabilities near $111–119B, and equity around $40–42B. Current assets vs. current liabilities are near parity, implying moderate liquidity and resilience against near-term shocks.
⚠️ Key Drivers & Risks
- Drivers: (1–2) Ongoing demand for health benefits and resilient enrollment trends; scale efficiencies in SG&A and cost structure.
- Risks: (1–2) Regulatory/policy changes and medical cost inflation; pricing competition and sensitivity to benefit costs.